C-reg

hurtkidsadness asked:

De ce Tumblr e aşa minunat? Ciudată întrebare? Nu? Ok. Adică frate, când intru aici parcă intru într-un univers din care nu mai vreau să plec, într-o lume în care găseşti persoane ca tine, într-o lume... de ce am lacrimi în ochii când sunt pe Tumblr?

Pentru că aici te regăseşti. Pentru că tumblr-ul e altfel de ceea ce e în viaţa reală. Pentru că aici poţ fi cine vrei să fi şi nimeni nu te judecă. Pentru că aici poţi visa. Pentru că aici sunt oameni care caută să fie înţeleşi. Pentru că aici e partea sensibilă şi frumoasă.

anonymous asked:

cum ai reusit sa aduni atatia urmaritori?? De cat timp ai blogul??

Sunt chiar puţini. De un an și ceva. Nu știu cum, poate că oamenii se regăsesc în posturile mele. Dacă ai timp și răbdare, scrollează mult în jos și mai am în jur de 1000+ posturi făcute de mine. Baftă

anonymous asked:

So MMBstated in an interview that she goes into her tag and someone got called out for posting a bery truthful submission reg C@ryl fans in the MMB tag. Maybe we should start tagging MMB in everything when it comes to all the hate? Make her aware that her fans are deranged, hypocritical asshats who harass and bully other fans and call her coworkers whom she adores slut, c*nt, pedo, pervert etc. please let us make her aware of her fans!

I have a feeling she is very much already aware of what her crazy fans say… She honestly deserves better fans.

“We are not naming our future baby Bruce.”

“Aw, c’mon, Reg, it’s Batman’s name. Batman.”

“Still nope. How about this name? Titania, the Fairy Queen.”

“Hmmm, nope. It’s a beautiful name, but not for a future Winters.”

“I thought our baby would be Black.”

“Nope! Future spawn of ours would be a Winters.”

“Well, you’re the boss.”

Emily Winters and Regulus Black talking about baby names. It didn’t matter that Emily wasn’t even pregnant or that they hadn’t even planned what would happen after they graduate of Hogwarts. They knew they would never leave each other anyway.

Taken by an Enchanted Camera

bellumnati asked:

positivity the dweeb aka part-time-justice-leaguer uwu

part-time-justice-leaguer 

i have never met sUCH A GOOD BATMAN NERD BEFORE LIKE THE BEST?? ONE WHO ACTUALLY CARES ABT THE CHARACTER AND NOT THOSE STUPID ‘WHO WOULD WIN IN A FIGHT BATMAN Or ____” FANS WHO ALWAYS USE ‘PREPTIME’ AS A DEUS EX 

also one who is emotionally invested in that fuckin bruce wayne gu y idk who that is ?? i guess he’s rich or smth

NO BUT SERIOUSLY REG IS GREAT. REG KNOWS BATMAN MORE THAN ANYONE ELSE I KNOW AN REG CARES AND HE UNDERSTANDS WHEN ITS LIKE 1 AM AND I CANT STOP SCREAMING BC SOMEONE WROTE MY OBSCURE AF FAVE AS OOC IN THSI ONE CARTOON 

REG IS A FANTASTIC WRITER AND WONDERBAT TRASH AND BOTH OF THESE THINGS ARE GREAT THINGS TO BE 

REG IS ALSO CHILL AF AND A GOOD FRIEND TO HAVE LIKE N I  C E 

REG ALLOWS FOR MY STUPID SU SCREAMING EVEN TH OUGH HE’S NEVER WATCHED A STEVEN UNIVERSE EPISODE IN HSI LIFE

REG IS A BLESSING TBH

transzformáció

nem tudom, olvasta-e valaki az Éjjeli Őrség című regényt. Klassz modern szovjet fantasy. Ebben a Setét (igen setét) erői a normál, hétköznapi emberek dühéből, fájdalmából nyernek erőt.

Na asszem így vagyunk mi is. 

Szívjuk…

A dugóban araszolók dühét, a háziorvosnál vagy hivatalban ücsörgőkét, némely csapágyas posztolókét, a szomszédét , a kollégákét. Aztán ezeket transzformáljuk cinizmussá, atyáskodó lenézéssé, meg ki tudja még mivé.  Néha még megértéssé , empátiává is.

Hangolódj a Kedves halottak!-ra

Ava Dellaira nemrég megjelent Kedves halottak! című regényében a főhős, Laurel elhunyt hírességeknek, köztük zenészeknek ír leveleket. Hogy ráhangolódjatok a könyvre, most mutatunk párat ezeknek az alkotóknak a számaiból.

Nirvana: Heart-Shaped Box


Amy Winehouse - You Know I’m No Good


Janis Joplin - Piece Of My Heart

Piedone pleacă din partidul lui Tăriceanu: „Nu mă regăsesc în ALDE. Mă leagă o frumoasă prietenie de Gabriel Oprea“

Primarul Sectorului 4 din Capitală, Cristian Popescu Piedone, a declarat miercuri că nu se regăseşte în ALDE, formaţiunea condusă de Călin Popescu Tăriceanu şi Daniel Constantin, în schimb, a precizat că este prieten cu Gabriel Oprea şi urmăreşte „interesul naţional“.

Surse politice au declarat, pentru Agerpres, că Piedone ar putea candida din partea UNPR, la alegerile locale din 2016. Cu o zi în urmă, primarul Sectorului 4 din Capitală anunţase că nu se regăseşte în ALDE.

„Mă leagă o frumoasă prietenie de Gabriel Oprea. Acum spun că urmăresc interesul naţional. După venirea mea din concediu, însemnând data de 15 septembrie, voi anunţa unde voi candida, pentru a se elimina speculaţiile la adresa mea. Anunţul pe care îl voi face privitor la candidatura mea nu îi va dezamăgi pe locuitorii sectorului 4, cărora le mulţumesc pentru încrederea acordată şi cărora le voi rămâne fidel în continuare. (…) Nu mă regăsesc în ALDE.

Cred că pe eşicherul politic este nevoie de o stângă şi o dreaptă care să lucreze împreună pentru interesul naţional şi consolidarea statului de drept. Cu atâtea războaie politice, România stă pe loc. Le urez mult succes colegilor mei care au ales să continue în ALDE, asigurându-i de tot respectul meu, dar eu aleg România“, a spus Piedone, citat de Agerpres.

Citeşte şi:

Alegerile locale din 2016, pe agenda PNL. Cine sunt candidaţii care se bat pentru cele şapte posturi de primar în Capitală

Conducerea PNL s-a reunit marţi, la Palatul Parlamentului, pentru a discuta despre candidaturile depuse de membrii formaţiunii în competiţia internă care va avea loc în perspectiva alegerilor locale din 2016.



Citeste si:
ANAF: Producători de medicamente aveau facturi de la firme de turism emise în baza unor acte fictiveFOTO Ponta, surprins la o cafenea, pe aeroportul din MiamiPrimul pugilist român calificat la Olimpiada din 2016. Relu Auraş: „Eu cred că Nistor poate câştiga o medalie“

anonymous asked:

So MMBstated in an interview that she goes into her tag and someone got called out for posting a bery truthful submission reg C@ryl fans in the MMB tag. Maybe we should start tagging MMB in everything when it comes to all the hate? Make her aware that her fans are deranged, hypocritical asshats who harass and bully other fans and call her coworkers whom she adores slut, c*nt, pedo, pervert etc. please let us make her aware of her fans!

Oh Gods.
I’m not going to post anything in her tag, that’s for sure.
People can do whatever their conscience lets them do.

Sunshine Heart Provides Update on Fully Implantable Circulatory Support System

EDEN PRAIRIE, Minn., July 30, 2015 (GLOBE NEWSWIRE) – Sunshine Heart (SSH) announced today an update on its next generation, fully implantable version of the Company’s flagship C-Pulse® technology. Sunshine Heart is pleased to report that it will commence a first-in-human study using the novel transcutaneous energy transmission (TET) system and a new smaller implantable pump in Q3 2016.

The study will initially enroll patients at hospitals outside the U.S., and will target patients suffering from advanced Class III/IV heart failure, similar to the patient population of Sunshine Heart’s current ongoing COUNTER HF™ Study. Feasibility of implant, safety and short term durability will be the primary objectives. Performance and efficacy data will be collected to evaluate patient quality of life, freedom from heart failure symptoms and other standard heart failure measures including the ability to bridge to other therapies.

Dr. William Cohn, Director of Center for Technology and Innovation, Texas Heart Institute, who has been involved since the inception of the program, will lead the study. Dr. Cohn commented that “the development of a completely implantable circulatory assist device that obviates the need for a driveline will be an important milestone in the evolution of heart failure therapies. The system will also be non-blood contacting and non-obligatory and may prove to be a real game changer for patients with intermediate stage heart failure.”

The development of a fully implantable system will eliminate the need to manage a driveline and will address the risk of exit site infections. Together with smaller and lighter wearable components, the system is designed to provide an improved quality of life for patients. The company believes this system will lead to increased market access to target all Class III HF patients, similar to CRM and neuromodulation devices. In addition, the unique ability to deliver chronic counterpulsation therapy and augment coronary blood flow, may afford a new market opportunity for the treatment of angina and ischemic heart disease where morbidity and mortality remain high in heart failure populations with reduced and preserved ejection fraction.*

The benefits of C-pulse and counterpulsation on the pulmonary circulation and the high prevalence of pulmonary hypertension in the latter population may also provide for a therapeutic opportunity with a fully implantable system in this large population with an unmet need.

*Moran, AE. The Global Burden of Ischemic Heart Disease in 1990 and 2013: The Global Burden of Disease 2013 Study. Circ. Cardiovasc. Qual. Outcomes, 2015.

*Clinical Characteristics and Outcomes of Patients with Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients with Heart Failure and Preserved Systolic Function Trial. - Badar AA, et al. Circ Heart Fail. 2015.

About the C-Pulse II (CPII) Fully Implantable System

The CPII system is designed to provide circulatory support for heart failure patients without making blood contact and without the need for a driveline. The system is based on the same extra-aortic counterpulsation principle as the C-Pulse® System to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. The system includes a small implanted pump that inflates and deflates the ascending aortic balloon with power provided across the patient’s skin by a TET system. Sunshine Heart has partnered with Cirtec Medical Systems (Los Gatos, Ca) and Minnetronix (St. Paul, MN) for the engineering development of the specialized pump and TET system.

About the C-Pulse®Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine®Heart

Sunshine Heart, Inc. (SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption “Risk Factors” and elsewhere in our filings with the U.S. Securities and Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

.gnwlistitemmarginbottom {margin-bottom: 10.0px !important;} .gnwtablebottommargin {margin-bottom: 10.0px !important;} .gnwcellpaddingleft0 {padding-left: 0.0px !important;} .gnwverticalaligntop {vertical-align: top !important;} .gnwtextaligncenter {text-align: center !important;} .gnwcellparagraphmargin {margin-bottom: 0px !important; margin-top: 0px !important;} .gnwverticalalignbottom {vertical-align: bottom !important;} .gnwwhitespacenowrap {white-space: nowrap !important;} .gnwtextalignright {text-align: right !important;} .gnwcellpaddingright0 {padding-right: 0.0px !important;} .gnwunderlinestyle {text-decoration: underline !important;} .gnwtextalignleft {text-align: left !important;} .gnw_heading {font: 16px Arial; text-align: center !important;} .gnw_subhead {font: 12px Arial; text-align: center !important;} td.gnw_colhead {font: 12px Arial; text-align: center !important;} td.gnw_colhead_uline {font: 12px Arial; text-align: center !important; border-bottom: solid black 1.0pt;} td.gnw_colhead_dline {font: 12px Arial; text-align: center !important; border-bottom: double black 2.5pt;} td.gnw_label {font: 12px Arial; vertical-align: bottom !important; text-align: left !important;} td.gnw_label_uline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_ulinetop {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-top: solid black 1.0pt;} td.gnw_label_dline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: double black 2.5pt;} td.gnw_label_i10 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 10.0px;} td.gnw_label_i15 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 15.0px;} td.gnw_label_i20 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 20.0px;} td.gnw_label_i25 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 25.0px;} td.gnw_label_i30 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 30.0px;} td.gnw_num {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important;} td.gnw_num_uline {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-bottom: solid black 1.0pt;} td.gnw_num_ulinetop {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-top: solid black 1.0pt;} td.gnw_num_dline {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-bottom: double black 2.5pt;} td.gnw_num_dlinetop {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-top: double black 2.5pt;} td.gnw_data {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; white-space: nowrap !important;} td.gnw_data_uline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: solid black 1.0pt;} td.gnw_data_dline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: double black 2.5pt;} .gnw_news_media_box {float: left !important; margin: 6px !important; border: solid 1px #a9a9a9 !important; width: 250px !important;} .gnw_media_caption {font-size: 8pt !important; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-Regular !important;} .gnw_media_bgcolor {background-color: transparent !important;} .gnw_table {border-collapse: separate !important; border-spacing: 6px !important;} .gnw_videotitle {font: bold 12px Arial !important; color: #1d5296 !important;} .gnw_ol {position: relative !important; left: 10px !important;} .gnw_ul {position: relative !important; left: 10px !important;} .gnw_border_top_solid {border-top: solid black 1px !important;} .gnw_border_right_solid {border-right: solid black 1px !important;} .gnw_border_bottom_solid {border-bottom: solid black 1px !important;} .gnw_border_left_solid {border-left: solid black 1px !important;} .gnw_border_top_double {border-top: double black 3px !important;} .gnw_border_right_double {border-right: double black 3px !important;} .gnw_border_bottom_double {border-bottom: double black 3px !important;} .gnw_border_left_double {border-left: double black 3px !important;} .gnw_table_border_collapse {border-collapse: collapse !important;} .gnw_table_border_collapse td {padding-left: 3px !important; padding-right: 3px !important;} .gnw_align_left {text-align: left !important;} .gnw_align_center {text-align: center !important;} .gnw_align_right {text-align: right !important;} .gnw_align_justify {text-align: justify !important;} .gnw_vertical_align_top {vertical-align: top !important;} .gnw_vertical_align_middle {vertical-align: middle !important;} .gnw_vertical_align_bottom {vertical-align: bottom !important;} ;}
Sunshine Heart to Release Second Quarter 2015 Results on August 4, 2015

EDEN PRAIRIE, Minn., July 28, 2015 (GLOBE NEWSWIRE) – Sunshine Heart, Inc. (SSH) today announced that its second quarter 2015 results will be released on Tuesday, August 4, 2015, before the open of the stock market. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company’s financial results and provide a general business overview.

To access the live webcast, please visit the Investors page of the Sunshine Heart website at http://ir.sunshineheart.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 88546172. An audio archive of the webcast will be available following the call at http://ir.sunshineheart.com.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine® Heart

Sunshine Heart, Inc. (SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

.gnwlistitemmarginbottom {margin-bottom: 10.0px !important;} .gnwtablebottommargin {margin-bottom: 10.0px !important;} .gnwcellpaddingleft0 {padding-left: 0.0px !important;} .gnwverticalaligntop {vertical-align: top !important;} .gnwtextaligncenter {text-align: center !important;} .gnwcellparagraphmargin {margin-bottom: 0px !important; margin-top: 0px !important;} .gnwverticalalignbottom {vertical-align: bottom !important;} .gnwwhitespacenowrap {white-space: nowrap !important;} .gnwtextalignright {text-align: right !important;} .gnwcellpaddingright0 {padding-right: 0.0px !important;} .gnwunderlinestyle {text-decoration: underline !important;} .gnwtextalignleft {text-align: left !important;} .gnw_heading {font: 16px Arial; text-align: center !important;} .gnw_subhead {font: 12px Arial; text-align: center !important;} td.gnw_colhead {font: 12px Arial; text-align: center !important;} td.gnw_colhead_uline {font: 12px Arial; text-align: center !important; border-bottom: solid black 1.0pt;} td.gnw_colhead_dline {font: 12px Arial; text-align: center !important; border-bottom: double black 2.5pt;} td.gnw_label {font: 12px Arial; vertical-align: bottom !important; text-align: left !important;} td.gnw_label_uline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; border-bottom: solid black 1.0pt;} td.gnw_label_ulinetop {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-top: solid black 1.0pt;} td.gnw_label_dline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: double black 2.5pt;} td.gnw_label_i10 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 10.0px;} td.gnw_label_i15 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 15.0px;} td.gnw_label_i20 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 20.0px;} td.gnw_label_i25 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 25.0px;} td.gnw_label_i30 {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; padding-left: 30.0px;} td.gnw_num {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important;} td.gnw_num_uline {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-bottom: solid black 1.0pt;} td.gnw_num_ulinetop {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-top: solid black 1.0pt;} td.gnw_num_dline {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-bottom: double black 2.5pt;} td.gnw_num_dlinetop {font: 12px Arial; vertical-align: bottom !important; text-align: right !important; white-space: nowrap !important; border-top: double black 2.5pt;} td.gnw_data {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; white-space: nowrap !important;} td.gnw_data_uline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: solid black 1.0pt;} td.gnw_data_dline {font: 12px Arial; vertical-align: bottom !important; text-align: left !important; border-bottom: double black 2.5pt;} .gnw_news_media_box {float: left !important; margin: 6px !important; border: solid 1px #a9a9a9 !important; width: 250px !important;} .gnw_media_caption {font-size: 8pt !important; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-Regular !important;} .gnw_media_bgcolor {background-color: transparent !important;} .gnw_table {border-collapse: separate !important; border-spacing: 6px !important;} .gnw_videotitle {font: bold 12px Arial !important; color: #1d5296 !important;} .gnw_ol {position: relative !important; left: 10px !important;} .gnw_ul {position: relative !important; left: 10px !important;} .gnw_border_top_solid {border-top: solid black 1px !important;} .gnw_border_right_solid {border-right: solid black 1px !important;} .gnw_border_bottom_solid {border-bottom: solid black 1px !important;} .gnw_border_left_solid {border-left: solid black 1px !important;} .gnw_border_top_double {border-top: double black 3px !important;} .gnw_border_right_double {border-right: double black 3px !important;} .gnw_border_bottom_double {border-bottom: double black 3px !important;} .gnw_border_left_double {border-left: double black 3px !important;} .gnw_table_border_collapse {border-collapse: collapse !important;} .gnw_table_border_collapse td {padding-left: 3px !important; padding-right: 3px !important;} .gnw_align_left {text-align: left !important;} .gnw_align_center {text-align: center !important;} .gnw_align_right {text-align: right !important;} .gnw_align_justify {text-align: justify !important;} .gnw_vertical_align_top {vertical-align: top !important;} .gnw_vertical_align_middle {vertical-align: middle !important;} .gnw_vertical_align_bottom {vertical-align: bottom !important;} ;}